The introduction of immune checkpoint inhibitors (ICIs), such as anti-PD-1, anti-PD-L1 and anti-CTLA-4, alone or in combination with chemotherapy, has been a breakthrough in oncology, with impressive clinical benefit in lung cancer and melanoma patients [15]. Here, CD274 is linked to lung carcinoma.